Literature DB >> 28251187

A review of drugs in development for the personalized treatment of head and neck squamous cell carcinoma.

Andrew C Birkeland1, Paul L Swiecicki2, J Chad Brenner1, Andrew G Shuman3.   

Abstract

INTRODUCTION: Head and neck squamous cell carcinoma remains a highly morbid and fatal disease, with poor survival rates among patients with advanced and recurrent disease. Recent advances in next generation sequencing, targeted therapeutics, and precision medicine trials are expanding treatment options for head and neck cancers; thus greater awareness of this rapidly evolving field is important. AREAS COVERED: Recent next-generation sequencing studies in head and neck squamous cell carcinoma, targeted therapy clinical trials involving head and neck squamous cell carcinoma. EXPERT COMMENTARY: This review discusses the current state of head and neck cancer treatment, and considerations and implications for the incorporation of personalized medicine and targeted therapy for head and neck cancers in a dynamic clinical landscape.

Entities:  

Keywords:  HNSCC; head and neck cancer; personalized medicine; precision medicine; targeted therapy

Year:  2016        PMID: 28251187      PMCID: PMC5328630          DOI: 10.1080/23808993.2016.1208050

Source DB:  PubMed          Journal:  Expert Rev Precis Med Drug Dev        ISSN: 2380-8993


  65 in total

1.  NCI-MATCH launch highlights new trial design in precision-medicine era.

Authors:  Caroline McNeil
Journal:  J Natl Cancer Inst       Date:  2015-07-03       Impact factor: 13.506

2.  Adverse events associated with concurrent chemoradiation therapy in patients with head and neck cancer.

Authors:  Daniel J Givens; Lucy Hynds Karnell; Anjali K Gupta; Gerald H Clamon; Nitin A Pagedar; Kristi E Chang; Douglas J Van Daele; Gerry F Funk
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2009-12

3.  Cetuximab activity in dysplastic lesions of the upper aerodigestive tract.

Authors:  Zubair Khan; Joel B Epstein; Shanthi Marur; M Boyd Gillespie; Lawrence Feldman; Hua-Ling Tsai; Zhe Zhang; Hao Wang; James Sciubba; Robert Ferris; Jennifer R Grandis; Michael Gibson; Wayne Koch; Ralph Tufano; William Westra; Nancy Tsottles; Hiroyuki Ozawa; Christine Chung; Joseph A Califano
Journal:  Oral Oncol       Date:  2015-12-10       Impact factor: 5.337

4.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Authors:  Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

5.  Distinct clinical course of EGFR-mutant resected lung cancers: results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib.

Authors:  Sandra P D'Angelo; Yelena Y Janjigian; Nicholas Ahye; Gregory J Riely; Jamie E Chaft; Camelia S Sima; Ronglai Shen; Junting Zheng; Joseph Dycoco; Mark G Kris; Maureen F Zakowski; Marc Ladanyi; Valerie Rusch; Christopher G Azzoli
Journal:  J Thorac Oncol       Date:  2012-12       Impact factor: 15.609

6.  Biomarkers in advanced larynx cancer.

Authors:  Carol R Bradford; Bhavna Kumar; Emily Bellile; Julia Lee; Jeremy Taylor; Nisha D'Silva; Kitrina Cordell; Celina Kleer; Robbi Kupfer; Pawan Kumar; Susan Urba; Francis Worden; Avraham Eisbruch; Gregory T Wolf; Theodoros N Teknos; Mark E P Prince; Douglas B Chepeha; Norman D Hogikyan; Jeffrey S Moyer; Thomas E Carey
Journal:  Laryngoscope       Date:  2013-07-12       Impact factor: 3.325

Review 7.  Cancer chemoresistance; biochemical and molecular aspects: a brief overview.

Authors:  Saeed Kachalaki; Mina Ebrahimi; Leila Mohamed Khosroshahi; Sina Mohammadinejad; Behzad Baradaran
Journal:  Eur J Pharm Sci       Date:  2016-04-16       Impact factor: 4.384

8.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

Authors:  Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar
Journal:  N Engl J Med       Date:  2004-06-03       Impact factor: 91.245

9.  Erlotinib and the Risk of Oral Cancer: The Erlotinib Prevention of Oral Cancer (EPOC) Randomized Clinical Trial.

Authors:  William N William; Vassiliki Papadimitrakopoulou; J Jack Lee; Li Mao; Ezra E W Cohen; Heather Y Lin; Ann M Gillenwater; Jack W Martin; Mark W Lingen; Jay O Boyle; Dong M Shin; Nadarajah Vigneswaran; Nancy Shinn; John V Heymach; Ignacio I Wistuba; Ximing Tang; Edward S Kim; Pierre Saintigny; Elizabeth A Blair; Timothy Meiller; J Silvio Gutkind; Jeffrey Myers; Adel El-Naggar; Scott M Lippman
Journal:  JAMA Oncol       Date:  2016-02       Impact factor: 31.777

10.  PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer.

Authors:  Cécile Badoual; Stéphane Hans; Nathalie Merillon; Cordélia Van Ryswick; Patrice Ravel; Nadine Benhamouda; Emeline Levionnois; Mevyn Nizard; Ali Si-Mohamed; Nicolas Besnier; Alain Gey; Rinat Rotem-Yehudar; Hélène Pere; Thi Tran; Coralie L Guerin; Anne Chauvat; Estelle Dransart; Cécile Alanio; Sebastien Albert; Beatrix Barry; Federico Sandoval; Françoise Quintin-Colonna; Patrick Bruneval; Wolf H Fridman; Francois M Lemoine; Stephane Oudard; Ludger Johannes; Daniel Olive; Daniel Brasnu; Eric Tartour
Journal:  Cancer Res       Date:  2012-11-07       Impact factor: 12.701

View more
  2 in total

1.  Whole-Exome Sequencing of Sinonasal Small Cell Carcinoma Arising within a Papillary Schneiderian Carcinoma In Situ.

Authors:  Joshua Smith; Aditi Kulkarni; Andrew C Birkeland; Jonathan B McHugh; J Chad Brenner
Journal:  Otolaryngol Head Neck Surg       Date:  2018-05-08       Impact factor: 3.497

Review 2.  Insights into Nanomedicine for Head and Neck Cancer Diagnosis and Treatment.

Authors:  Cláudia Viegas; Daniela S M Pereira; Pedro Fonte
Journal:  Materials (Basel)       Date:  2022-03-11       Impact factor: 3.623

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.